Q-omics provides the consensus-scored DTX4 profile across patient tissues and cancer cell-line models. DTX4 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, DTX4 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, DTX4 RNA expression shows 19,917 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight THCA, and TGCT as cancer lineages where DTX4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DTX4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DTX4 survival associations across molecular data types. DTX4 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DTX4 RNA expression–survival associations across cancer types. High DTX4 expression shows unfavorable associations in UVM, CESC and LUSC, but favorable associations in THCA, LGG and BLCA. The THCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for DTX4 RNA expression.
This table summarizes DTX4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for DTX4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DTX4 shows lower tumor expression in KICH and LUAD and higher tumor expression in THCA, KIRC, STAD and BLCA. The THCA box plot shows higher DTX4 RNA expression in tumor versus normal tissue (log2 FC = +3.392, t-test p < 0.001).
This table shows molecular features associated with DTX4 in patient tissues and cancer cell lines. In patient samples, DTX4 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, DTX4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Lymphoma.
